CervoMed Inc. entered into a securities purchase agreement on June 9, 2026, for a private placement of 3,360,377 units, consisting of common stock or pre-funded warrants, Series B warrants, and Series C warrants. The gross proceeds are expected to be approximately $10.5 million, with potential additional proceeds of up to $21.7 million from warrant exercises. The company expects to use the net proceeds to fund research and development of its clinical-stage product candidate, neflamapimod, and for working capital. CervoMed Inc. is a clinical-stage biotechnology company focused on developing therapeutic solutions.
